Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.0223.63%
OTC PK
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -30.26% | -37.20% | -42.27% | 58.04% | 82.76% |
Total Depreciation and Amortization | 136.51% | 114.58% | 94.19% | -3.79% | -52.57% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 17.92% | 69.88% | 100.42% | -81.36% | -95.69% |
Change in Net Operating Assets | 5.72% | 115.16% | 100.78% | 108.95% | 127.69% |
Cash from Operations | -34.03% | 10.55% | 27.49% | 54.06% | 72.69% |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -100.00% | 0.00% | -- | -- | -- |
Other Investing Activities | -2,300.00% | -3,275.00% | -6,200.00% | 98.30% | 100.09% |
Cash from Investing | -19,500.00% | -29,075.00% | -57,800.00% | 83.15% | 100.09% |
Total Debt Issued | -- | -84.01% | -- | -- | -- |
Total Debt Repaid | -75.34% | -8.40% | 19.98% | 48.91% | 68.95% |
Issuance of Common Stock | 78.83% | 39.58% | 22.35% | -32.18% | -69.10% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -1,106.38% | -491.86% | -301.21% | -89.17% | 75.58% |
Cash from Financing | 73.31% | -0.59% | -22.68% | -55.94% | -78.91% |
Foreign Exchange rate Adjustments | -220.79% | -146.61% | -120.14% | -88.69% | -71.27% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 88.60% | 130.00% | 582.99% | 2.66% | -71.11% |